NeurogesX, Inc. (Nasdaq:NGSX) announced that the FDA has accepted for review the its supplemental new drug application (sNDA) for Qutenza (capsaicin) 8 percent, for the management of neuropathic pain associated with HIV-associated peripheral neuropathy (HIV-PN). The FDA has granted Qutenza a priority six month review classification, assigning a Prescription Drug User Fee Act (PDUFA) action date of March 7, 2012.